Principal Investigator(s):Souleymane Mboup, Ph.D. RARS, Geoffrey S Gottlieb, M.D, Moussa Sarr, M.D., MPH
Objective:The investigators propose a HIV PrEP demonstration project in FSW in Dakar, Senegal, West Africa. The objective of the proposed demonstration project with Tenofovir DF/Emtricitabine (TDF/FTC) among Female Sex Workers (FSW) in Dakar Senegal is to build a sustainable HIV PrEP program for FSW in Dakar, Senegal while demonstrating the feasibility of providing daily oral PrEP with Truvada (TDF/FTC) for 12 months to the enrolled FSW at Ministry of Heath run clinics (IHS, and Pikine, Mbao, Rufisque and Diamniadio Health Centers). Critical milestones for this demonstration project with be feasibility, uptake, acceptability, use of TDF/FTC PrEP and programmatic retention of FSWs in Dakar MoH clinics. The investigators have assembled an expert team from RARS,The University of Washington, and Westat that have had greater than 2 decades of collaboration on HIV related projects in FSWs in Senegal. The investigators expect the results of this project will show that Senegal provides a unique opportunity to assess acceptability, feasibility, uptake and effectiveness of oral HIV PrEP at reducing HIV transmission in a high-risk FSW population.
Study Design:Open label
Official Code: NCT02474303
Trial Sponsors: Bill & Melinda Gates Foundation, Réseau Africain de Recherche sur le SIDA, University of Washington, Westat
July 1, 2015
October 31, 2016
Age range: 18 Years ↔ any